Results 81 to 90 of about 53,933 (241)

Origin and diversification of steroids: Co-evolution of enzymes and nuclear receptors [PDF]

, 2010
Recent sequencing of amphioxus and sea urchin genomes has provided important data for understanding the origins of enzymes that synthesize adrenal and sex steroids and the receptors that mediate physiological response to these vertebrate steroids ...
Michael E. Baker
core   +1 more source

Bile acids and nonalcoholic fatty liver disease: An intriguing relationship [PDF]

, 2016
Non-alcoholic fatty liver disease (NAFLD) stands nowadays as a leading cause of progressive impairment of liver function. The role of bile acids in the modulation of hepatic lipid metabolism is interesting and controversial; previous evidence showed an ...
Gabbi, Lonardo, Nagahashi, Watanabe
core   +1 more source

Progress of metabolomics‐centric multi‐omics research in medicine

iMetaOmics, EarlyView.
The graphical abstract illustrates a holistic roadmap for metabolomics‐centric multi‐omics integration in medical research. The upper panel depicts the technological transition from traditional bulk analysis to high‐resolution single‐cell and spatial methodologies, specifically addressing inherent challenges such as molecular complexity and dynamic ...
Ziyi Wang, Shiwen Deng, Xiaoxu Wang, Xiao Chang, Na Guo, Peng Chen, Hongjun Yang   +6 more
wiley   +1 more source

Caveolin-1 protects B6129 mice against Helicobacter pylori gastritis. [PDF]

, 2013
Caveolin-1 (Cav1) is a scaffold protein and pathogen receptor in the mucosa of the gastrointestinal tract. Chronic infection of gastric epithelial cells by Helicobacter pylori (H. pylori) is a major risk factor for human gastric cancer (GC) where Cav1 is
A Bist, A Lee, A Muller, AB Rogers, AS Day, B Razani, C Pelz, C Wunder, CG Hansen, CH Kuo, CH Lai, CH Lai, Christoph Röcken, Claus Schäfer, CM Rosenberger, D Engel, D Forman, D Makola, DW Zaas, E Burgermeister, E Burgermeister, E Burgermeister, E Prade, E Touati, E Touati, Elke Burgermeister, F Lian, F Sommer, FA Medina, FA Medina, FA Medina, Florian Anderl, FS Machado, G Li, G Soong, Gang Yuan, I Mercier, I Regel, IC Arnold, IC Arnold, IC Arnold, IM Toller, Ivana Hitkova, J Li, J Millan, JC Atherton, JE Crabtree, JG Fox, JH Chidlow Jr, JP Boettcher, JS Low, JW Yam, K Ohnuma, K Simons, K Yuan, KM Bourzac, LJ Thompson, M Beigier-Bompadre, M Gadjeva, M Hatakeyama, M Kurayoshi, M Mohammadi, M Yamaga, Markus Gerhard, Matthias P. A. Ebert, MF Dixon, MJ Zhang, ML Hutton, MM D'Elios, MP Ebert, MP Ebert, MR Amieva, NE van Doorn, OA Senkovich, P Gargalovic, P Kundu, P Lajoie, PU Le, R Palovuori, R Rad, R Tsutsumi, Roger Vogelmann, Roland M. Schmid, S Li, S Moese, S Thomas, Simone Reu, Steven R. Blanke, T Kawazoe, T Tomassian, TH Tsai, Thomas Kirchner, TI Jeon, TM Williams, TM Williams, TY Kim, VM Pietiainen, W Schraw, X Cao, X Xing, Y Churin, Y Mitsuno, Y Yamaoka, YC Liao   +103 more
core   +4 more sources

Beyond Tradition: An Integrated Toxicological, Ecological, and Public Health Perspective on Aristolochic Acids

Journal of Applied Toxicology, EarlyView.
ABSTRACT Aristolochia species have long been used in traditional medicine for their presumed anti‐inflammatory, analgesic and antimicrobial properties. However, extensive toxicological and epidemiological evidence now demonstrates that these plants contain aristolochic acids (AAs) I and II, highly potent nephrotoxic, genotoxic, and carcinogenic ...
Victor Ventura de Souza, Lara Rodrigues De Andrade, Tatiana da Silva Souza   +2 more
wiley   +1 more source

Bile acids at the cross-roads of gut microbiome–host cardiometabolic interactions [PDF]

, 2017
This work is supported in part by the APC Microbiome Institute (under Science Foundation Ireland [SFI] Grant Number: SFI/12/RC/2273) and by Enterprise Ireland Commercialization Fund (Contract Reference: CF/2013/3030A/B).peer-reviewedWhile basic and ...
Caplice, Noel M, Ryan, Paul M, STANTON, CATHERINE   +2 more
core   +3 more sources

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source

Exploration of Hepatoprotective Effect of Gentiopicroside on Alpha-Naphthylisothiocyanate-Induced Cholestatic Liver Injury in Rats by Comprehensive Proteomic and Metabolomic Signatures

Cellular Physiology and Biochemistry, 2018
Background/Aims: Cholestasis is the major cause of the accumulation of bile acids and results in liver damage, fibrosis, and failure. A growing number of studies have shown that gentiopicroside is a promising prospect that may protect the liver. However,
Han Han, Lili Xu, Kai Xiong, Tong  Zhang, Zhengtao Wang   +4 more
doaj   +1 more source

Pharmacotherapy for Nonalcoholic Fatty Liver Disease [PDF]

, 2015
Lifestyle modifications and optimization of the management of cardiometabolic comorbidities are currently the mainstay of treatment for patients with nonalcoholic fatty liver disease.
Chalasani, Naga, Gawrieh, Samer
core   +2 more sources

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, EarlyView.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source